Statins and their roles in cancer

Drugs of Today

Volumn 41, Issue 5, 2005, Pages 329-334

  Lam, Laura ^a   Cao, Ying ^a  

^a BioMedSci Consulting   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ATORVASTATIN; CERIVASTATIN; FLUINDOSTATIN; HYDROXYMETHYLGLUTARYL COENZYME A REDUCTASE INHIBITOR; MEVINOLIN; PRAVASTATIN; SIMVASTATIN;

ACUTE HEART FAILURE; ANTINEOPLASTIC ACTIVITY; ARTERY DISEASE; BREAST CANCER; CANCER INCIDENCE; CANCER RISK; CLINICAL TRIAL; COLON CANCER; CORONARY ARTERY DISEASE; DIABETES MELLITUS; DRUG FATALITY; DRUG SAFETY; HEART INFARCTION; HUMAN; HYPERCHOLESTEROLEMIA; ISCHEMIC HEART DISEASE; LIPOPHILICITY; LIVER CELL CARCINOMA; LONG TERM CARE; LUNG CANCER; LYMPHOMA; MELANOMA; META ANALYSIS; NONHUMAN; PROSTATE CANCER; REVIEW; SKIN CANCER; VASCULAR DISEASE;

ANTICARCINOGENIC AGENTS; CLINICAL TRIALS; HUMANS; HYDROXYMETHYLGLUTARYL-COA REDUCTASE INHIBITORS; NEOPLASMS;

EID: 23044438402     PISSN: 16993993     EISSN: 16994019     Source Type: Journal    
DOI: 10.1358/dot.2005.41.5.893617     Document Type: Review

References (23)

1. Maron, D.J., Fazio, S., Linton, M.F. Current perspectives on statins. Circulation 2000, 101: 207-13.
2. Hebert, P.R., Gaziano, J.M., Chan, K.S., Hennekens, C.H. Cholesterol lowering with statin drugs, risk of stroke, and total mortality. An overview of randomized trials. JAMA 1997, 278:313-21.
3. Chan, K.K.W., Oza, A.M., Siu, L.L. The statins as anticancer agents. Clin Cancer Res 2003, 9: 10-9.
4. Wong, W.W., Dimitroulakos, J., Minden, M.D., Penn, L.Z. HMG-CoA reductase inhibitors and the malignant cell: The statin family of drugs as triggers of tumor-specific apoptosis. Leukemia 2002, 12: 508-19.
5. Newman, T.B., Hulley, S.B. Carcinogenicity of lipid-lowering drugs. JAMA 1996, 275: 55-60.
6. Sacks, P.M., Pfeffer, M.A., Moye, L.A. et al. The effect of pravastatin on coronary events after myocardial infarction inpatients with average cholesterol levels. Cholesterol and Recurrent Events Trial investigators. N Engl J Med 1996, 335: 1001-9.
7. Downs, J., Clearfield, M., Weis, S. et al. Primary prevention of acute coronary events with lovastatin in men and women with average cholesterol levels: Results of AFCAPS/Tex-CAPS. Air Force/Texas Coronary Atherosclerosis Prevention Study. JAMA 1998, 279: 1615-22.
8. Heart Protection Study Collaborative Group. MRC/BHF Heart Protection Study of cholesterol lowering with simvastatin in 20,536 high-risk individuals: A randomized placebo-controlled trial. Lancet 2002, 360: 7-22.
9. ALLHAT Officers and Coordinators for the ALLHAT Collaborative Research Group. The antihypertensive and Lipid-Lowering Treatment to Prevent Heart Attack Trial. Major outcomes in moderately hypercholesterolemic, hypertensive patients randomized to pravastatin vs usual care: The antihypertensive and Lipid-Lowering Treatment to Prevent Heart Attack Trial (ALLHAT-LLT). JAMA 2002, 288: 2998-3007.
10. Sever, P.S., Dahlof, B., Poulter, N.R. et al. ASCOT investigators. Prevention of coronary and stroke events with atorvastatin in hypertensive patients who have average or lower-than-average cholesterol concentrations, in the Anglo-Scandinavian Cardiac Outcomes Trial-Lipid Lowering Arm (ASCOT-LLA): A multicentre randomized controlled trial. Lancet 2003, 361: 1149-58.
11. Bjerre, L., LeLorier, J. Do statins cause cancer? A meta-analysis of randomized clinical trials. Am J Med 2001, 110: 716-23.
12. Scandinavian Simvastatin Survival Study Group. Randomized trial of cholesterol lowering in 4444 patients with coronary heart disease: The Scandinavian Simvastatin Survival Study (4S). Lancet 1994, 344: 1383-9.
13. The Long-Term Intervention with Pravastatin in Ischaemic Disease (LIPID) Study Group. Prevention of cardiovascular events and death with pravastatin in patients with coronary heart disease and a broad range of initial cholesterol levels. N Engl J Med 1998, 339: 1349-57.
14. Shepherd, J., Cobbe, S.M., Ford, I. et al. Prevention of coronary heart disease with pravastatin in men with hypercholesterolemia. West of Scotland Coronary Prevention Study Group. N Engl J Med 1995, 333: 1301-7.
15. Biais, L., Desgagne, A., LeLorier, J. 3-Hydroxy-3-methylglutaryl coenzyme A reductase inhibitors and the cancer risk. Arch Intern Med 2000, 160: 2363-8.
16. Boudreau, D.M., Gardner, J.S., Malone, K.E., Heckbert, S.R., Blough, D.K., Daling, J.R. The association between 3-hydroxy-3-methylglutaryl conenzyme A inhibitor use and breast carcinoma risk among postmenopausal women: A case-control study. Cancer 2004, 100: 2308-16.
17. Graaf, M.R., Beiderbeck, A.B., Egberts, A.C., Richel, D.J., Guchelaar, H.J. The cancer risk in users of statins. J Clin Oncol 2004, 22: 2388-94.
18. Kawata, S., Yamasaki, E., Nagase, T. et al. Effect of pravastatin on survival in patients with advanced hepatocellular carcinoma. A randomized controlled trial. Br J Cancer 2001, 84: 886-91.
19. Larner, J., Jane, J., Laws, E. A phase I-II trial of lovastatin for anaplastic astrocytoma and glioblastoma multiforme. Am J Clin Oncol 1998, 21: 579-83.
20. Rao, S., Porter, D.C., Chen, X., Herliczek, T., Lowe, M., Keyomarsi, K. Lovastatin-mediated G1 arrest is through inhibition of the proteasome, independent of hydroxymethyl glutaryl-CoA reductase. Proc Natl Acad Sci USA 1999, 96: 7797-802.
21. Wheeler, D.C. Are there potential non-lipid-lowering uses of statins? Drugs 1998, 56: 517-22.
22. Chan, K.K., Oza, A.M., Siu, L.L. The statins as anticancer agents. Clin Cancer Res 2003, 9: 10-9.
23. Splichal, J.E., Stamm, J.A., Ornstein, D.L. The statins: Multifunctional antithrombotic and antineoplastic drugs. Seminars in Thrombosis and Hemostasis 2003, 29: 259-74.